- New Jersey-based therapeutics company Celularity is awaiting permission from the FDA to test whether a cancer treatment could be effective against COVID-19.
- The cell therapy works by boosting the body’s early immune response in a way that could target the coronavirus.
- The company transforms placental stem cells into one-size-fits-all “Natural Killer” cells that act as sentinels and keep the virus from replicating out of control.
- Some researchers caution that the strategy is highly uncertain and potentially risky, but if the treatment proves safe and effective, Celularity will ramp up production quickly.
Source: https://www.cnbc.com/2020/03/31/cell-therapy-to-fight-covid-19-awaits-fda-approval-for-clinical-trial.html
